Nanobiotix Prices $98.6M Global Offering at Discount, Extends Cash Runway to 2029

summarizeSummary

Nanobiotix priced its oversubscribed global offering, raising $98.6 million at a discount to market, which is expected to fund operations into 2029.

check_boxKey Events

• Global Offering Priced

  Nanobiotix priced its global follow-on offering, consisting of ADSs and ordinary shares, at $38.98 per ADS and €33.60 per ordinary share. This represents a 14.92% discount to the three-day volume-weighted average price.

• $98.6 Million Capital Raised

  The offering is expected to generate approximately $98.6 million in gross proceeds, with a potential increase to $100 million if the over-allotment option is fully exercised.

• Cash Runway Extended to 2029

  The company anticipates that the net proceeds, combined with existing cash, will be sufficient to fund operations and meet working capital requirements into 2029.

• Oversubscribed with Shareholder Support

  The offering was oversubscribed and received support from existing major shareholders, including Qatar Holding LLC and Invus, as well as other healthcare specialist investors.

auto_awesomeAnalysis

Nanobiotix has finalized the terms of its global follow-on offering, successfully raising $98.6 million. This capital infusion is critical for the company, extending its cash runway into 2029 and supporting the advancement of its nanotechnology platforms and JNJ-1900 development. While the offering was priced at a 14.92% discount to the three-day volume-weighted average price, the oversubscribed nature and support from existing major shareholders like Qatar Holding LLC and Invus demonstrate confidence in the company's long-term prospects despite the dilutive impact on existing shareholders.